Item 5.02 Departure of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective June 15, 2021 the Board of Directors (the "Board") of AtriCure, Inc. (the "Company") elected Deborah H. Telman and Maggie Yuen to serve as Directors until the next Annual Meeting of Stockholders. The Board has determined that each of Ms. Telman and Ms. Yuen is an independent director in accordance with guidelines that the Company has adopted, which also comply with the listing standards set forth by The NASDAQ Stock Market. Ms. Telman was appointed to the Nominating and Corporate Governance Committee; Ms. Yuen was appointed to the Audit Committee.

Ms. Telman has served as the General Counsel of Organon & Co. (NYSE: OGN) since March 2021. Previously, Ms. Telman served as Senior Vice President, General Counsel & Corporate Secretary of Sorrento Therapeutics, Inc., a biopharmaceutical company, from 2018 to 2020. Prior to joining Sorrento, Ms. Telman held several senior executive roles at Johnson Controls International plc, a multinational building technology and solutions company, including Vice President & General Counsel, Building Solutions North America and Global Retail, from 2017 to 2018; Vice President & General Counsel, Corporate Legal Services, from 2016 to 2017; and Vice President & General Counsel, Centers of Excellence-Americas, from 2014 to 2015. Before Johnson Controls, Ms. Telman was at Abbott Laboratories in the position of Divisional Vice President, Associate General Counsel, from 2013 to 2014 and Division Counsel, Corporate Transactions, from 2009 to 2012. She also served as Chief Counsel, Mergers & Acquisitions at The Boeing Company, from 2002 to 2008 and was a Partner at Winston & Strawn LLP between 2000 and 2002. Ms. Telman is a graduate of the University of Pennsylvania and received her J.D. from Boston University School of Law.

Ms. Yuen has served as the Chief Financial Officer of Penumbra, Inc. (NYSE: PEN) since December 2019. Prior to joining Penumbra, Ms. Yuen spent more than 20 years driving scalable finance organizations, processes and infrastructure in the Manufacturing, Medical Devices, and Life Science industries. She served as Vice President of Finance of the Genetic Science Division within Thermo Fisher Scientific, Inc. (NYSE: TMO) (Thermo Fisher), a business focused on instrument platforms, cloud-based software, content and services, from 2016 to 2019. In her role, Ms. Yuen directed finance operations, strategic planning and business development activities, among a number of other executive functions. Prior to Thermo Fisher, Ms. Yuen held leadership positions with increasing responsibility at Mirion Technologies (from 2012 to 2016), and senior finance roles at Boston Scientific (NYSE: BSX) (from 2007 to 2010), Glu Mobile (Nasdaq: GLUU) (from 2004 to 2007), and Johnson & Johnson (NYSE: JNJ) (from 2001 to 2004). She received an MAcc and M.B.A. from the Weatherhead School of Management and a B.S. from Case Western Reserve University.

There is no arrangement or understanding between Ms. Telman or Ms. Yuen and any other person pursuant to which they were elected as Directors of the Company, and there have been no transactions nor are there any proposed transactions between the Company and Ms. Telman or Ms. Yuen that would require disclosure pursuant to Item 404(a) of Regulation S-K. Ms. Telman and Ms. Yuen will receive compensation for their service as directors in accordance with the Company's compensation policies for non-employee directors as described in the Company's proxy materials for its 2021 Annual Meeting of Stockholders.

A copy of the press release announcing Ms. Telman's and Ms. Yuen's election is furnished as Exhibit 99.1 and incorporated by reference in this Item 5.02

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



No.      Description

99.1       AtriCure Press Release dated June 15, 2021
104      Cover Page Interactive Data File--the cover page XBRL tags are embedded
         within the Inline XBRL document.



                                       ?

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses